To test whether BX-795 exerts a direct effect on Ser473, we generated a non-phosphorylatable Thr308 form of Akt, HA-asAkt T308A . HEK293 cells transfected with either HA-asAkt1 T308A , HA-asAkt2
T309A
or HA-asAkt3 T305A were treated with 2.5 μM BX-795 for 10 min prior to the addition of 2.5 μM PrIDZ for an additional 30 min. Cell lysates were analyzed for Akt (Ser473, Thr308) phosphorylation by immunoblotting. BX-795 did not inhibit hyperphosphorylation induced by PrIDZ, indicating that BX-795 does not affect Ser473 phosphorylation in Akt hyperphosphorylation directly. Although BX-795 inhibits PDGFR alpha in vitro as well (Supplementary Table 1 online), it is unlikely that the inhibition we observe at Thr308 in Fig. 3e is derived from PI3K inhibition through the inhibition of PDGFR alpha. If BX-795 inhibition of PDGFR alpha in cells was the basis for blocking Akt phosphorylation we would expect to see inhibition of Ser473 hyperphosphorylation (since PDGFR alpha is upstream of PI3K) in the HA-asAkt T308A as was seen with PIK90 (pan-PI3K inhibitor) treatment (Fig. 3b) . BX-795 also inhibits Aurora kinases (Supplementary Table 1 online), however we do not anticipate an effect of these targets when BX-795 is used at short time points to study the growth factor pathway. We note that BX-795 exhibits slightly different dose dependent shifts in Thr-308 phosphorylation inhibition in the three Akt isoforms (Fig. 3e) . Inhibition of asAkt1 Thr308 hyperphosphorylation by BX-795 is rather weak whereas BX-795 inhibition at Thr308 is very potent on asAkt2 and asAkt3. No selective direct S6K inhibitors were available to test whether inhibition of S6K would trigger Akt hyperphosphorylation. We therefore searched the patent literature for reports of S6K inhibitors and after the synthesis of several candidates we identified DG2 (7) . (a) Structure and IC 50 values of DG2. This compound exhibits a 9.1 nM IC 50 value for S6K1 and only minimal off-target effects against 220 kinases (Supplementary Table 1 Either myr-HA-asAkt1/2 or myr-HA-asAkt1/2-KD was transiently expressed (a) in MCF7, (b) in MiaPaCa-2 or (c) in PC-3. The cells were serum starved over night before treatment for 30 min with 2.5 μM PrIDZ in media without serum or growth factors. Cell lysates were analyzed for Akt (Ser473, Thr308) phosphorylation by immunoblotting. In general, hyperphosphorylation on myr-HA-asAkt2-KD was somewhat weaker than the catalytically active variant, myr-HA-asAkt2. A possible explanation of reduced hyperphosphorylation on myr-asAkt2-KD is that introduction of the kinase inactivating mutation (D289A in Akt2) located in the active site and could affect conformation of drug binding site, resulting in a lowered affinity for the drugs. In MCF-7 and PC-3 cells, hyperphosphorylation on myr-HA-asAkt1 and myr-HA-asAkt1-KD did not show highly efficient drug induction. These cell lines are transformed and have activated PI3K or PTEN deficiency which causes an increase in basal Thr308 and Ser473 site phosphorylation decreasing the level of possible induction of new phosphorylation. 
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Supplementary Figure 7.
Hyperphosphorylation is induced on flag-wtAkt1 by A-443654 and on flag-asAkt1 by PrIDZ. HEK293 cells transfected with either flag-wtAkt1 or flag-asAkt1 were treated for 30 min with 2.5 μM A-443654 or 2.5 μM PrIDZ, respectively. Cell lysates were analyzed for Akt (Ser473, Thr308) phosphorylation by immunoblotting. As a control, the same treatment was applied to untransfected HEK293 cells with A-443654. Hyperphosphorylation was observed both on flag-wtAkt1 or flag-asAkt1, confirming the ability of flag-tagged Akt1 to become hyperphosphorylated by Akt inhibitors. HEK293T and HEK293 cells were cultured overnight with or without serum starvation, and then the starved cells were stimulated with IGF-1 for 10 min. Cell lysates were analyzed for Akt (Ser473 and Thr308) and GSK3β (Ser9) phosphorylation by immunoblotting. 
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Plasmid constructs
pcDNA3-myr-HA-Akt1/2/3 were kind gifts from W. Sellers via Addgene (Akt1/2/3 -Addgene plasmid 9008/9016/9017). Since these constructs had a point mutation in the HA tag, these plasmids were used after repairing the mutation with a modified method of Stratagene 
General synthetic methods
Unless otherwise noted, all reactions were performed under argon and stirred magnetically in oven-dried glassware fitted with rubber septa. All 3-Iodophenylacetic acid (5.24 g, 20.0 mmol, 9) was dissolved in hexane (100 ml). DMF (146 mg, 2.0 mmol) were added, followed by the dropwise addition of oxalyl chloride (12.7 g, 100 mmol).
After gas evolution had stopped (ca. 30 min), the solvent was removed under reduced pressure.
The acid chloride 10 was redissolved by rinsing the reaction mixture with THF. To a clean 100 ml round bottom flask NaH (1.06 g, 44.0 mmol) was added in 10 ml THF and the mixture was cooled to 0°C. Malononitrile (1.45 g, 22.0 mmol) was dissolved in THF (10 ml) and added dropwise to the NaH/THF suspension. The THF solution of acid chloride generated above was added dropwise to the malononitrile solution with vigorous stirring. After 1 h the residue was added to approximately 15 ml of 1N H 2 SO 4 and 50 ml H 2 O, before being extracted with EtOAc (3 x 100 ml). The EtOAc extracts were combined, dried over MgSO 4 , and evaporated to yield 11 (4.20 g) as a yellow oil that was carried to the next step without further purification. To a solution of 11 (3.10 g, 10.0 mmol) in dioxane (18 ml) and water (3 ml) was added NaHCO 3 (6.8 g).
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Dimethyl sulfate (4.9 ml) was added with vigorous stirring and the reaction mixture was heated at 100°C on an oil bath for 2 h. The cooled reaction mixture was diluted with water (70 ml) and extracted with Et 2 O (3 x 100 ml). give a yellow solid. The yellow residue was filtered through silica gel with 2:1 CHCl 3 /hexanes to yield 13 (1.52 g) as a white solid. Formamide (10 ml) was added to 13 (1.14 g, 3.0 mmol). The mixture was heated to 180°C on an oil bath and stirred for 10 h. The cooled reaction mixture was diluted with water (40 ml) and the precipitate was collected by filtration. The precipitate was redissolved in hot EtOH, which was decolorized over activated charcoal and filtered.
Evaporation of EtOH yielded 3-IB-PP1 (2) (0.93 g, 76%) as a white powder. 
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Synthesis of PrIDZ (3) To a solution of 19 (4.1 g, 15.7 mmol) in dioxane (50 ml) was added MnO 2 (6.8 g, 78.5 mmol).
After stirring for 9 h at 90°C, the reaction mixture was filtered through celite and concentrated.
The resulting residue was purified by column chromatography on silica gel (hexane-EtOAc gradient) to afford 20 as yellow oil (3.9 g, 15.1 mmol, 96%). To a solution of 20 (2.0 g, 7.72 mmol) in DMF (10 ml) was added hydrazine monohydrate (7.5 ml, 154 mmol). After stirring for 24 h at 120°C, the reaction was diluted with EtOAc. 46/50 Synthesis of 2- (4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl) -1H-indol-5-ol (PP242, 6) was carried out as reported previously 7 . 
Synthesis of DG2 (7)
DG2
